Drugs / CLM2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03994406 | Jun → Aug 2019 | corneal disorder, ocular hyperemia | Glia, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLM2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03994406 ↗ |
| Route | Topical | “CLM2 topical gel to be applied dermally to forehead twice daily” NCT03994406 ↗ |